{"id":33140,"date":"2024-03-23T20:01:28","date_gmt":"2024-03-23T14:31:28","guid":{"rendered":"https:\/\/farratanews.online\/newly-approved-cancer-drug-targets-aggressive-form-of-deadly-disease\/"},"modified":"2024-03-23T20:01:28","modified_gmt":"2024-03-23T14:31:28","slug":"newly-approved-cancer-drug-targets-aggressive-form-of-deadly-disease","status":"publish","type":"post","link":"https:\/\/farratanews.online\/newly-approved-cancer-drug-targets-aggressive-form-of-deadly-disease\/","title":{"rendered":"Newly approved cancer drug targets aggressive form of \u2018deadly disease\u2019"},"content":{"rendered":"

[ad_1]\n<\/p>\n

\n

A new drug regimen for certain types of pancreatic cancer<\/u> recently received approval from the U.S. Food and Drug Administration (FDA) \u2014 the first new medication in nearly a decade.<\/p>\n

Onivyde (irinotecan liposome), an injectable medication made by Ipsen, has been approved for use along with oxaliplatin, fluorouracil and leucovorin as a regimen for patients with metastatic pancreatic adenocarcinoma (mPDAC).<\/p>\n

This type of cancer is an aggressive malignancy with an average life expectancy of between eight and 11 months, according to the National Institutes of Health (NIH).<\/p>\n

ON THIS DAY IN HISTORY, MARCH 6, 2019, ALEX TREBEK SHARES CANCER DIAGNOSIS WITH THE WORLD<\/u><\/strong><\/p>\n

The approval was based on a randomized, controlled trial<\/u> that included 770 patients with metastatic pancreatic adenocarcinoma who had not previously received chemotherapy, according to an FDA press release.<\/p>\n

The group of patients who received the new regimen via IV infusion showed “significant improvements” in survival rates and response rates compared to the control group.<\/p>\n

\n
\"Woman<\/source><\/source><\/source><\/source><\/picture><\/div>\n
\n
\n

A new drug regimen for certain types of pancreatic cancer recently received approval from the U.S. Food and Drug Administration.<\/span> (iStock)<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

The drug regimen is administered via IV for 90-minute sessions every two weeks.<\/p>\n

“I am hopeful that this regimen represents a new reference \u2014 meaning we will add to this in the future,” Dr. Zev Wainberg, professor of medicine and co-director of the UCLA GI Oncology Program in Los Angeles, told Fox News Digital.<\/p>\n

AI SHOWN TO PREDICT RISK OF PANCREATIC CANCER WELL BEFORE SYMPTOMS APPEAR<\/u><\/strong><\/p>\n

“We needed clarity on the data before proceeding, which the Phase 3 trial provides.”<\/p>\n

Metastatic pancreatic cancer<\/u> is one of the most difficult cancers to treat, Wainberg noted, as it doesn\u2019t respond as well to new drugs that work in other types of the disease.\u00a0<\/p>\n

“Patients are unfortunately often quite sick, and many cancers move too fast for a drug to work as they might in other cancers,” he noted.<\/p>\n

\n
\"Pancreatic<\/source><\/source><\/source><\/source><\/picture><\/div>\n
\n
\n

Metastatic pancreatic cancer is one of the most difficult cancers to treat, a doctor noted, as it doesn\u2019t respond as well to new drugs that work in other types of the disease.\u00a0<\/span> (iStock)<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center<\/u> and a Fox News medical contributor, said the drug is “a useful new tool, but not a game-changer.”<\/p>\n

“It works well in conjunction with other chemotherapies that have been used for widespread pancreatic cancer,” Siegel told Fox News Digital.\u00a0<\/p>\n

“It works by interfering with DNA replication in the cancer and by damaging the tumor\u2019s DNA repair.”<\/p>\n

COULD A URINE TEST DETECT PANCREATIC AND PROSTATE CANCER? STUDY SHOWS 99% SUCCESS RATE<\/u><\/strong><\/p>\n

Dr. Peter Hosein, M.D., associate director of clinical research at the University of Miami\u2019s Sylvester Comprehensive Cancer Center\u2019s Pancreatic Cancer Research Institute, also commented on the new approval.<\/p>\n

“Pancreatic cancer is a deadly disease where meaningful progress is sorely needed in prevention, early detection and treatment to improve outcomes,” he told Fox News Digital.<\/p>\n

\n
\"IV<\/source><\/source><\/source><\/source><\/picture><\/div>\n
\n
\n

The group of patients who received the new regimen via IV infusion showed “significant improvements” in survival rates and response rates compared to the control group.<\/span> (iStock)<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

Onivyde is a new formulation of an old drug that is “almost identical,” Hosein said.<\/p>\n

“So, although this is a new approval, it does not really represent meaningful progress,” he told Fox News Digital.\u00a0<\/p>\n

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER<\/u><\/strong><\/p>\n

Onivyde is also “substantially more expensive” than Irinotecan, the existing standard medication<\/u>, Hosein pointed out.\u00a0<\/p>\n

“There are many doctors and scientists working around the clock on this disease and the survival rates are slowly improving,” he said.\u00a0<\/p>\n

“We need to continue focusing on breakthrough therapies that will truly move the needle to help our patients.”\u00a0<\/p>\n

\n
\"Alzheimer's<\/source><\/source><\/source><\/source><\/picture><\/div>\n
\n
\n

“There are many doctors and scientists working around the clock on this disease and the survival rates are slowly improving,” a doctor said of pancreatic cancer.<\/span> (iStock)<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n

The most commonly reported side effects of Onivyde are diarrhea, nausea, vomiting, fatigue, decreased appetite, abdominal pain, mucosal inflammation, constipation and weight loss, the FDA stated.\u00a0<\/p>\n

“All drugs have a safety profile that needs to be taken seriously,” Wainberg said.\u00a0<\/p>\n

CLICK HERE TO GET THE FOX NEWS APP<\/u><\/strong><\/p>\n

“Here, most of the combination produced GI upset<\/u> \u2014 diarrhea and sometimes dehydration \u2014 so prophylactic (preventative) management is critical.”<\/p>\n

Fox News Digital reached out to Ipsen, a French biopharmaceutical company headquartered in Paris, France, for additional comment.<\/p>\n

For more Health articles, visit <\/u><\/strong><\/i>www.foxnews.com\/health<\/u><\/strong><\/i>.<\/strong><\/i><\/p>\n

<\/p>\n

\n
\n

Melissa Rudy is health editor and a member of the lifestyle team at Fox News Digital. Story tips can be sent to melissa.rudy@fox.com.<\/p>\n<\/div>\n<\/div>\n<\/div>\n[ad_2]\n","protected":false},"excerpt":{"rendered":"

[ad_1] A new drug regimen for certain types of pancreatic cancer recently received approval from the U.S. Food and Drug Administration (FDA) \u2014 the first new medication in nearly a decade. Onivyde (irinotecan liposome), an injectable medication made by Ipsen, has been approved for use along with oxaliplatin, fluorouracil and leucovorin as a regimen for …<\/p>\n","protected":false},"author":1,"featured_media":33141,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[],"_links":{"self":[{"href":"https:\/\/farratanews.online\/wp-json\/wp\/v2\/posts\/33140"}],"collection":[{"href":"https:\/\/farratanews.online\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/farratanews.online\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/farratanews.online\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/farratanews.online\/wp-json\/wp\/v2\/comments?post=33140"}],"version-history":[{"count":0,"href":"https:\/\/farratanews.online\/wp-json\/wp\/v2\/posts\/33140\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/farratanews.online\/wp-json\/wp\/v2\/media\/33141"}],"wp:attachment":[{"href":"https:\/\/farratanews.online\/wp-json\/wp\/v2\/media?parent=33140"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/farratanews.online\/wp-json\/wp\/v2\/categories?post=33140"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/farratanews.online\/wp-json\/wp\/v2\/tags?post=33140"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}